Private Equity

Providence Care's new CEO is a former therapist. Can his clinical insight solve market challenges and deliver on a private equity growth plan?

Capital Power unveils a $3B deal with Apollo to buy U.S. gas plants while securing a major deal to power Alberta's AI boom, a bold dual strategy.

A novel drug for heart failure shows promising safety and efficacy data, potentially disrupting a multi-billion dollar market and validating a key investor's strategy.

Bill Ackman's fund is buying back its own shares at a deep discount. We explore the innovative financial strategy and its impact on shareholder value.

Denali Therapeutics raises $200M to advance its brain-penetrating drugs, betting big on its pipeline despite short-term market jitters.

Following stellar clinical data, Terns Pharmaceuticals' upsized $650M offering signals massive investor confidence and funds its push to disrupt the CML market.

Major hotel chains are now building integrated living ecosystems for digital nomads. What does this pivot to wellness mean for the future of care?

BNY Mellon's steady dividend offers a window into the high-yield debt market, a crucial, high-risk funding source for the mining sector's energy transition.

Beyond a simple payout, Qnity Electronics' increased dividend reveals its deep financial strength and strategic position fueling the AI and HPC revolution.

Beyond a simple FDA approval, Amneal's entry into the epinephrine vial market is a calculated move to fix a broken supply chain and drive growth.

Condor Energies secures $10M in a high-stakes financing to fast-track its Uzbekistan gas program. A deep dive into the strategy, risks, and what it means.

A routine dividend from Morgan Stanley's China A-Share fund offers a deeper look into the risks and rewards of investing in China's domestic market.

As AI-native fintech Henon plants its flag in London, its push for 'zero-error' finance signals a new competitive era for private capital in EMEA.

A century-old brand just launched a giant, novelty product. It’s not a joke—it’s a calculated lesson in modern marketing and brand revitalization.

A regulatory filing from Balyasny Asset Management reveals intense investor activity as a bidding war for narcolepsy drugmaker Avadel heats up.

A routine UK disclosure by an investment giant has pulled back the curtain on a major transatlantic auto merger and the silent influence of institutional capital.

A regulatory filing from Weiss Asset Management reveals a complex arbitrage play on Alphawave IP, spotlighting its critical role in the Qualcomm deal.

A $2.4B tech acquisition seems distant from healthcare, but Qualcomm's move to buy Alphawave is building the essential AI infrastructure for medicine's future.

A class-action suit claims Primo Brands hid merger problems behind a perfect narrative. This is a deep dive into corporate spin and shareholder risk.

OTC-listed Lelantos Holdings, known for renewables, bets its future on a historic Arizona gold-copper mine. A strategic pivot or a high-stakes gamble?